Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
Carisma Therapeutics (CARM) Stock Price & Analysis
1,480 Followers
CARM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $9.77
Previous Close$1.41
Volume131.76K
Average Volume (3M)172.49K
Market Cap
$58.58M
Enterprise Value-$15.91M
Total Cash (Recent Filing)$77.61M
Total Debt (Recent Filing)$3.12M
Price to Earnings (P/E)-0.7
Beta1.27
Next Earnings
Aug 08, 2024EPS Estimate
-$0.3Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding41,542,744
10 Day Avg. Volume183,400
30 Day Avg. Volume172,494
Standard Deviation0.31
R-Squared0.03
Alpha0.00638
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)0.70
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.17
Enterprise Value/Gross Profit-0.17
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$7.60Price Target Upside439.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Carisma Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company ended the quarter with $56.5MM in cash and cash equivalents, expected to provide a runway into 3Q25.
Product DevelopmentInitial clinical data suggests that the CT-0508/pembro combination is encouraging for treating solid tumors.
Strategic CollaborationsIn vivo collaboration with Moderna progresses toward development candidate.
Bears Say
Company RestructuringCARM announced a reduction in workforce by 37%, which may signal cost-cutting measures due to financial constraints.
Drug Efficacy ConcernsSteroid administration likely reversed the effects of CT-0508 in the initial patients, potentially confounding efficacy results.
Pipeline SetbacksThe company is ceasing further development of its lead candidate, CT-0508, and prioritizing CT-0525, which has not yet entered the clinic.
---
Ownership Overview
61.91%
Insiders
6.43% Mutual Funds
13.42% Other Institutional Investors
18.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $1.34 and its highest was $9.77 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Currently, no data Available
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 79 days.
How were Carisma Therapeutics’s earnings last quarter?
Currently, no data Available
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.36 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -$0.3.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,542,744 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Carisma Therapeutics?
Among the largest hedge funds holding Carisma Therapeutics’s share is Hussman Strategic Advisors Inc. It holds Carisma Therapeutics’s shares valued at N/A.
---
Carisma Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.60 (439.01% Upside)
$7.60 (439.01% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.41%
12-Months-Change
Fundamentals
Return on Equity
-167.51%
Trailing 12-Months
Asset Growth
-52.74%
Trailing 12-Months
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Month Forecast
Average Price Target
$7.60
▲(439.01% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Editas Medicine
―
Sangamo Biosciences
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-35.75%
reiterated a buy rating 13 days ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.75% per trade.
---